BlackRock’s Akero Therapeutics AKRO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-5,702,634
| Closed | -$271M | – | 5536 |
|
|
2025
Q3 | $271M | Sell |
5,702,634
-76,778
| -1% | -$3.72M | ﹤0.01% | 1484 |
|
|
2025
Q2 | $308M | Sell |
5,779,412
-475,612
| -8% | -$21.6M | 0.01% | 1349 |
|
|
2025
Q1 | $253M | Buy |
6,255,024
+330,841
| +6% | +$14M | 0.01% | 1460 |
|
|
2024
Q4 | $165M | Buy |
5,924,183
+176,393
| +3% | +$5.34M | ﹤0.01% | 1775 |
|
|
2024
Q3 | $165M | Buy |
5,747,790
+161,153
| +3% | +$4.2M | ﹤0.01% | 1775 |
|
|
2024
Q2 | $131M | Buy |
5,586,637
+694,021
| +14% | +$14.8M | ﹤0.01% | 1868 |
|
|
2024
Q1 | $124M | Buy |
4,892,616
+712,109
| +17% | +$17.1M | ﹤0.01% | 1947 |
|
|
2023
Q4 | $97.6M | Buy |
4,180,507
+203,187
| +5% | +$4.01M | ﹤0.01% | 2091 |
|
|
2023
Q3 | $201M | Buy |
3,977,320
+656,167
| +20% | +$30.6M | 0.01% | 1546 |
|
|
2023
Q2 | $155M | Buy |
3,321,153
+537,776
| +19% | +$24.6M | ﹤0.01% | 1760 |
|
|
2023
Q1 | $106M | Buy |
2,783,377
+24,848
| +0.9% | +$1.11M | ﹤0.01% | 1976 |
|
|
2022
Q4 | $151M | Buy |
2,758,529
+413,052
| +18% | +$17.7M | ﹤0.01% | 1724 |
|
|
2022
Q3 | $79.9M | Buy |
2,345,477
+254,236
| +12% | +$3.89M | ﹤0.01% | 2112 |
|
|
2022
Q2 | $19.8M | Buy |
2,091,241
+195,713
| +10% | +$2.04M | ﹤0.01% | 3088 |
|
|
2022
Q1 | $26.9M | Sell |
1,895,528
-48,594
| -2% | -$851K | ﹤0.01% | 2983 |
|
|
2021
Q4 | $41.1M | Buy |
1,944,122
+77,565
| +4% | +$1.72M | ﹤0.01% | 2784 |
|
|
2021
Q3 | $41.7M | Buy |
1,866,557
+18,709
| +1% | +$424K | ﹤0.01% | 2778 |
|
|
2021
Q2 | $45.8M | Buy |
1,847,848
+383,030
| +26% | +$10.8M | ﹤0.01% | 2761 |
|
|
2021
Q1 | $42.5M | Buy |
1,464,818
+117,914
| +9% | +$3.57M | ﹤0.01% | 2723 |
|
|
2020
Q4 | $34.8M | Sell |
1,346,904
-6,854
| -0.5% | -$191K | ﹤0.01% | 2697 |
|
|
2020
Q3 | $41.7M | Buy |
1,353,758
+323,776
| +31% | +$11.3M | ﹤0.01% | 2405 |
|
|
2020
Q2 | $25.7M | Buy |
1,029,982
+309,868
| +43% | +$7.08M | ﹤0.01% | 2667 |
|
|
2020
Q1 | $15.3M | Buy |
720,114
+180,215
| +33% | +$3.87M | ﹤0.01% | 2745 |
|
|
2019
Q4 | $12M | Buy |
539,899
+232,043
| +75% | +$4.8M | ﹤0.01% | 3153 |
|
|
2019
Q3 | $7M | Buy |
307,856
+161,694
| +111% | +$3.76M | ﹤0.01% | 3382 |
|
|
2019
Q2 | $2.8M | Buy |
+146,162
| New | +$2.77M | ﹤0.01% | 3671 |
|
Other funds holding AKRO
BlackRock's AKRO Position: Q4 2025 in Review
BlackRock sold out of Akero Therapeutics (AKRO) in Q4 2025, closing a stake of 5,702,634 shares — an estimated $271M sold.
BlackRock first reported a position in AKRO in Q2 2019 and held it in 26 quarters. The position peaked at $308M in Q2 2025. 2 funds tracked by Wall St. Rank hold AKRO as of Q4 2025.
- BlackRock reported no remaining Akero Therapeutics position as of Q4 2025 after selling out during the quarter.
- BlackRock sold 5,702,634 Akero Therapeutics shares in Q4 2025, an estimated $271M.
- BlackRock first reported a position in Akero Therapeutics in Q2 2019 and held it in 26 quarters.
- BlackRock's Akero Therapeutics position peaked at $308M in Q2 2025.
- 2 funds tracked by Wall St. Rank held Akero Therapeutics as of Q4 2025.
Based on BlackRock's 13F filing for Q4 2025, filed 12 Feb 2026.